Background
==========

Identification of immune biomarkers indicating potential clinical benefit from immunotherapies may contribute to the selection of the right patient for the right therapy. We have recently reported that HLA-DRB1\*11 and HLA-A\*24 alleles might serve as predictive factors for immunological and clinical responses to vaccination with AE37, the Ii-Key hybrid peptide of HER2~776-790~ (AE36) in prostate cancer patients. The purpose of this study was to investigate the predictive significance of DRB1\*11 allele expression in relation to immunological and clinical response in breast cancer patients vaccinated with AE37 in a randomized Phase II clinical trial.

Methods
=======

This trial (ClinicalTrials.gov Identifier: NCT00524277) enrolled node-positive or high risk node-negative patients with any degree of HER2 expression (IHC 1-3+ or FISH \> 1.2), rendered disease-free following standard of care therapy. Patients were randomized to receive either AE37+GM-CSF (vaccine group) or GM-CSF alone (control group) in 6 monthly intradermal primary inoculations followed by 4 boosters administered every 6 months. The current analysis includes data from 55 patients enrolled and vaccinated with AE37 in Greece, where the frequency of HLA-DRB1\*11 is high. HLA-typing and measurement of TGFβ levels in serum were performed using Luminex® technology. Immunologic responses were assessed *in vivo* using the delayed-type hypersensitivity (DTH) test and *in vitro* with IFN-γ ELISPOT assay.

Results
=======

Of the 55 vaccinated pts, 31 were found to be DRB1\*11+ (56%). At baseline prior to vaccination, 22% (12 out of 55) of the vaccinated patients demonstrated pre-existing immunity against AE36 by IFN-γ release (defined as above the 75th percentile of all enrolled patients). Among patients with pre-existing AE36 immunity, the majority, 67% (8 out of 12), were found to be DRB1\*11^+^. Vaccine-induced DTH and IFNγ responses, were augmented in the vast majority of DRB1\*11+ patients. No correlation was observed between the pre-existing levels of serum TGFβ and the expression of the DRB1\*11 allele. With a median follow up of 71 months, Kaplan-Meir analyses demonstrated a 22% and 72% relative reduction in recurrence rate (RRR) in DRB1\*11^+^ patients and those with pre-existent immunity, respectively. Overall survival analysis of DRB1\*11^+^ patients showed a 50% relative reduction in death rate (RRD), and a 74% RRD in patients with pre-existent immunity.

Conclusions
===========

Our data demonstrate both immunologic and clinical advantage of vaccination therapy with AE37 among patients expressing DRB1\*11 and/or having pre-existing HER2 immunity, highlighting their potential roles as predictive biomarkers to select patients most likely to benefit from vaccination with AE37.

Trial Registration
==================

ClinicalTrials.gov identifier NCT00524277.
